Form 4: Celularity Director Peter Diamandis Reports Stock and Option Grants

Director Peter Diamandis reports the acquisition of restricted stock units and stock options in Celularity Inc.

Summary

• Peter Diamandis, a director of Celularity Inc., filed a Form 4 detailing changes in beneficial ownership.
• On December 19, 2024, Diamandis acquired 67,416 shares of Class A Common Stock in the form of Restricted Stock Units (RSUs) and options to purchase 84,746 shares.
• The RSUs and options were granted under the Celularity Inc. 2021 Equity Incentive Plan.
• These RSUs and options vest on the earlier of December 19, 2024 (one-year anniversary of the grant date), or the next annual stockholder meeting, contingent upon continuous service with the Issuer.
• Following the reported transactions, Diamandis beneficially owns 1,374,482 shares of Class A Common Stock and options to purchase 362,524 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of equity suggests confidence in the company's future, but it's a routine transaction.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service with the company.

Future Outlook

The vesting of the RSUs and stock options is contingent upon the Reporting Person's continuous service with the Issuer, suggesting an expectation of continued involvement.

Industry Context

Stock grants and options are a common form of executive compensation in the biotechnology industry, aligning management's interests with shareholder value creation.

Stakeholder Impact

• The equity grants could potentially increase shareholder value if the company performs well.
• The vesting schedule incentivizes the director to remain with the company, benefiting employees and other stakeholders.

Key Dates